ganirelix acetate
ApprovedSmall molecule
ganirelix acetate is one of 37 small molecule programs targeting Polycystic Ovary Syndrome. It is currently in Approved.
2
Indications
11
Total Trials
2
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
175 competitors in Polycystic Ovary Syndrome
#DrugCompanyPhaseTrials
1Farxiga
AstraZenecaPhase 3
Glucophage
Boehringer IngelheimPhase 3
ganirelix acetate
YYale University
Approved
Clomid
FerringPreclinical
Precose
BayerPreclinical
Proglycem
TevaPreclinical
Clomid
EMD SeronoPreclinical
Cetrotide
EMD SeronoPreclinical
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Tricor
JJagotec
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Ovarian Stimulation2 trials
Efficacy and Safety1 trial
GAN1 trial
Cetrorelix and Ganirelix Flexible Protocol for (IVF)
Unknown status·—·Phase 4·NCT03477929·100 enrolled
4 more indications
Progestin-primed Ovarian Stimulation1 trial
Polycystic Ovary Syndrome1 trial
Estrogen1 trial
Unspecified2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ganirelix acetate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- YYale University